Lanreotide Drug Level
| Label Mnemonic: | LANREO |
| Epic code: | LAB8729 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Plasma
Specimen
Instructions:
For optimal results, draw immediately before IV (trough level).
Collection Medium:
 |
| Pink top tube 6 mL (K2-EDTA) |
Minimum:
1 mL plasma
Reference Range:
Mean lanreotide levels +/- 2SD for patients on Somatuline Depot®
injections for 4 or more months (steady-state). The following values
represent trough levels of lanreotide measured immediately before a
patient's next injection of Somatuline Depot.
Lanreotide administered as Somatuline® Depot:
480 mg/month: 20,000 pg/mL + 2,000 pg/mL
240 mg/month: 10,000 pg/mL + 2,000 pg/mL
120 mg/month: 5,000 pg/mL + 1,000 pg/mL
90 mg/month: 2,500 pg/mL + 500 pg/mL
Lanreotide administered as Somatuline® Depot:
480 mg/month: 20,000 pg/mL + 2,000 pg/mL
240 mg/month: 10,000 pg/mL + 2,000 pg/mL
120 mg/month: 5,000 pg/mL + 1,000 pg/mL
90 mg/month: 2,500 pg/mL + 500 pg/mL
Comments:
Lanreotide (Somatuline Depot®, Tercica) is used for the control
of symptoms associated with functional neuroendocrine tumors. Frequent
measurement of the lanreotide levels may be useful in guiding therapy
in patients with poorly controlled symptoms or those patients
experiencing tumor growth. Lanreotide levels in blood need to be in a
specific range to be effective. Measuring lanreotide immediately prior
to the monthly injection will determine trough levels of the drug in
your blood.
Methodology:
Lanreotide is measured by direct radioimmunoassay.
CPT Code:
83519